Integrated DNA Technologies Opens new San Diego Oligonucleotide Production Center
News Jan 26, 2006
Integrated DNA Technologies (IDT) have further expanded its oligonucleotide production capabilities with the official opening of IDT West Coast Operations in San Diego. Participating at the event were San Diego Regional Economic Development Corporation CEO Julie Meier Wright, and Joe Panetta, CEO of BIOCOM who joined IDT President Dr. Joseph Walder in cutting the ribbon that marks the company’s arrival in one of the nation’s key biotech communities.
IDT West Coast Operations gives the California biotech industry immediate access to IDT’s next-day oligo production capability and allows the company to further capitalize on its increasing market share.
"San Diego has built a great reputation as one of the world’s leading biotech centers," noted San Diego Regional EDC’s CEO Julie Meier Wright. "IDT’s decision to locate its first satellite production facility here is a testament to the vibrancy of our life science and research community. We look forward to working with the new IDT West Coast Operation as they use their expertise to enhance the quality of research undertaken across the region."
The establishment of IDT West Coast Operations represents the latest step in a new phase of growth for Integrated DNA Technologies. As Dr. Walder said, "The San Diego biotech industry continues to expand and improve.
Given its growing needs, and the quality of work undertaken across this region, we recognized the value in establishing a physical presence here. IDT West Coast Operations allows us to add a locally accessible next-day order fulfillment service to the product and support quality we have always provided our customers."
IDT West Coast Operations is the result of Integrated DNA Technologies acquisition of San Diego based GenBase, Inc. in December 2005. GenBase’s facility was absorbed into IDT’s new 10,000 sq. ft. production center and the Coralville, Iowa based company has moved to quickly introduce its own proprietary custom nucleic acid production equipment and processes.
Currently IDT West Coast Operations employs 16 people, and plans to double that number within the next 12 months.
"Researchers know that IDT represents the best in oligo synthesis, quality assurance, and customer support," said Dan Dernbach, recently appointed general manager of IDT’s new division. "Now, with our new West Coast Operations we’ve brought that quality standard and QC excellence to the next-day service sector at the heart of California’s oligo market."
IDT is also expanding its headquarters in Coralville, Iowa with a 77,000 square foot extension, due for completion in February. Effectively doubling that center’s research, support and production capacity, the new expansion will allow IDT to better cater to increasing market demand for its products by augmenting its customer service and order fulfillment departments.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.